

# XXVI Symposium IACRLRD

International Association for  
Comparative Research on  
Leukemia and Related Diseases



TORINO, LINGOTTO CONFERENCE CENTER  
SEPTEMBER 11-14, 2013

PROGRAM

Under the Auspices of

REGIONE PIEMONTE

COMUNE DI TORINO

AIL - ASSOCIAZIONE ITALIANA CONTRO LE LEUCEMIE - LINFOMI E MIELOMA ONLUS

AIL - ASSOCIAZIONE ITALIANA CONTRO LE LEUCEMIE - LINFOMI E MIELOMA  
SEZIONE DI TORINO

ELN - EUROPEAN LEUKEMIA NET

SIE - SOCIETÀ ITALIANA DI EMATOLOGIA

SIES - SOCIETÀ ITALIANA DI EMATOLOGIA SPERIMENTALE

# XXVI Symposium IACRLRD

International Association for Comparative Research on  
Leukemia and Related Diseases



TORINO, LINGOTTO CONFERENCE CENTER  
SEPTEMBER 11-14, 2013

## Officers of the Association 2011 - 2013

<i>President</i>	Giuseppe Saglio, Italy
<i>Vice Presidents</i>	François Guilhot & Hervé Dombret, France
<i>Secretary General</i>	Clara D. Bloomfield, USA
<i>Chair Nominating Committee</i>	Rüdiger Hehlmann, Germany
<i>Treasurer</i>	Russell de Burlo, USA
<i>Legal Council</i>	Harry Hüge, USA

## World Scientific Committee

Cestmir Altaner	Slovakia
Charles Bangham	United Kingdom
Andrea Biondi	Italy
Anton Berns	The Netherlands
Michael Caligiuri	USA
Carmino De Souza	Brazil
Hartmut Döhner	Germany
Hervé Dombret	France
Genoveffa Franchini	USA
Jacques Ghysdael	France
David Grimwade	United Kingdom
François Guilhot	France
William Hall	Ireland
Eva Hellström-Lindberg	Sweden
Andreas Hochhaus	Germany
Hagop Kantarjian	USA
Michael Lairmore	USA
Francesco Lo Coco	Italy
Michael Lübbert	Germany
Roland Mertelsmann	Germany
Tomoki Naoe	Japan
Jesus F. San Miguel	Spain
Arinobu Tojo	Japan
Anna Turkina	Russia

## Faculty

Cestmir	Altaner	Bratislava, Slovaccchia
Sergio	Amadori	Rome, Italy
Kenneth C.	Anderson	Wellesley, USA
Jane F.	Apperley	London, United Kingdom
Charles R.M.	Bangham	London, United Kingdom
Tiziano	Barbui	Bergamo, Italy
Bart	Barlogie	Little Rock, USA
Giovanni	Barosi	Pavia, Italy
Andrea	Biondi	Monza (MI), Italy
Clara D.	Bloomfield	Columbus, USA
Mario	Boccardo	Torino, Italy
Alan K.	Burnett	Cardiff, United Kingdom
Arsène	Burny	Bruxelles, Belgium
Federico	Caligaris-Cappio	Milano, Italy
Michael A.	Caligiuri	Columbus, USA
Clara	Camaschella	Milano, Italy
Maria Domenica	Cappellini	Milano, Italy
Angelo Michele	Carella	Genova, Italy
Mario	Cazzola	Pavia, Italy
Francisco	Cervantes	Barcelona, Spain
Luigi	Chieco Bianchi	Padova, Italy
Daniela	Cilloni	Orbassano (TO), Italy
Jan	Cools	Leuven, Belgium
Paolo	Corradini	Milano, Italy
Riccardo	Dalla Favera	New York, USA
Carmino	De Souza	Campinas, Brazil
Hartmut	Döhner	Ulm, Germany
Konstanze	Döhner	Ulm, Germany
Hervé	Dombret	Paris, France
Franca	Fagioli	Torino, Italy
Brunangelo	Falini	Perugia, Italy
Felicetto	Ferrara	Napoli, Italy
Robin	Foà	Roma, Italy
Genoveffa	Franchini	Bethesda, USA
Francesco	Frassoni	Genova, Italy
Gianluca	Gaidano	Novara, Italy
Robert Peter	Gale	Los Angeles, USA
Andrea	Gallamini	Cuneo, Italy
Alfredo	Garzino Demo	Baltimore, USA
Paolo	Ghia	Milano, Italy
Jacques	Ghysdael	Orsay, France
Francis	Giles	Chicago, USA
John M.	Goldman	London, United Kingdom
David	Grimwade	London, United Kingdom
François	Guilhot	Poitiers, France
Joëlle	Guilhot	Poitiers, France
Rüdiger	Hehlmann	Mannheim, Germany
Eva	Hellström-Lindberg	Stockholm, Sweden
Andreas	Hochhaus	Jena, Germany



Dieter	Hoelzer	Frankfurt, Germany
Wolf-Karsten	Hofmann	Mannheim, Germany
VAmY	Johnson	Columbus, USA
Hitoshi	Kiyoi	Nagoya, Japan
H. Phillip	Koeffler	Los Angeles, USA
Nicholas	Kröger	Hamburg, Germany
Richard A.	Larson	Chicago, USA
Ross	Levine	New York, USA
Marina	Liberati	Perugia, Italy
Francesco	Lo Coco	Roma, Italy
Michael	Lübbert	Freiburg, Germany
Lucio	Luzzatto	Firenze, Italy
François-Xavier	Mahon	Bordeaux, France
Guido	Marcucci	Columbus, USA
Giovanni	Martinelli	Bologna, Italy
Roland	Mertelsmann	Freiburg, Germany
Emili	Montserrat	Barcelona, Spain
Alessandro	Morotti	Torino, Italy
Tariq	Mughal	Boston, USA
Martin C.	Müller	Mannheim, Germany
Arnon	Nagler	Tel Aviv, Israel
Tomoki	Naoe	Nagoya, Japan
Oliver G.	Ottmann	Frankfurt, Germany
Antonio P.	Palumbo	Torino, Italy
Pier Paolo	Pandolfi	Boston, USA
Fabrizio	Pane	Napoli, Italy
Francesco	Passamonti	Varese, Italy
Günter	Pasternak	Teupitz, Germany
Danilo	Perrotti	Columbus, USA
Antonio	Piga	Orbassano (TO), Italy
Eliezer A.	Rachmilewitz	Holon, Israel
Davide	Rossi	Novara, Italy
Gianantonio	Rosti	Bologna, Italy
Stefano	Sacchi	Modena, Italy
Giuseppe	Saglio	Orbassano (TO), Italy
Valeria	Santini	Firenze, Italy
Charles	Schiffer	Detroit, USA
Simona	Soverini	Bologna, Italy
Giorgina	Specchia	Bari, Italy
Corrado	Tarella	Torino, Italy
Arinobu	Tojo	Tokyo, Japan
Sante	Tura	Bologna, Italy
Anna	Turkina	Moscow, Russia
William	Vainchenker	Villejuif, France
Richard	Van Etten	Medford, USA
Alessandro M.	Vannucchi	Firenze, Italy
Norbert	Vey	Marseille, France
Toshiki	Watanabe	Tokyo, Japan
Elena	Zamagni	Bologna, Italy

# Wednesday, September 11, 2013

11:00 AM - 12:30 PM

## Session 1: Biologic and molecular characterization of Acute Myeloid Leukemia

Chairmen: Clara Bloomfield, Sante Tura

- Secondary AML
- Clinical impact of NPM1 mutations in AML
- Prognostic impacts and clonal heterogeneity of recurrently identified mutations in AML
- The role of the microenvironment in ALs

Valeria Santini  
Konstanze Döhner  
  
Hitoshi Kiyoi  
Jacques Ghysdael

12:30 PM - 1:00 PM

## Kenneth McCredie Memorial Lecture

Introduction: Roland Mertelsman

Clinical significance of prognostic molecular markers in adult AML

Clara Bloomfield

1:00 PM - 2:00 PM      **Lunch**

2:00 PM - 4:00 PM

## Session 2: Treating Acute Myeloid Leukemia today

Chairmen: Alan K. Burnett, Charles Schiffer

- Is APL a cured disease-what are the future challenges?
- Treatment options for AML in the elderly
- How should we manage AML in adolescents and young adults (AYA)?
- Who should be transplanted in first remission of AML?
- Genotype-adapted treatment trials in AML-Concepts of the AMLSG

Francesco Lo Coco  
Sergio Amadori  
  
Richard Larson  
  
Alan K. Burnett  
  
Hartmut Döhner

4:00 PM - 5:00 PM      **Open Coffee**



4:00 PM - 6:00 PM

## Session 3: Treating Acute Myeloid Leukemia tomorrow

Chairmen: Cestmir Altaner, Tomoki Naoe

- Therapeutic targeting of miR-associated mechanisms in AML
- Targeting mutated epigenetic modifiers in AML
- Where can we really use MRD in AML (excluding APL)?
- The future for immune therapy in AML. Stop being so negative
- GVHD and GVL: perspectives to modulate them in allotransplant for AML

Guido Marcucci  
Ross Levine

David Grimwade

Michael Caligiuri

Arnon Nagler

6:00 PM - 6:30 PM

## Yohei Ito Memorial Lecture

Introduction: Tomoki Naoe

Is the new molecular subgrouping of AML clinically helpful and can new, specifically targeted, AML drugs be developed?

Charles Schiffer

6:30 PM - 8:00 PM

Opening Ceremony and Welcome Cocktail

# Thursday, September 12, 2013

8:15 AM - 10:15 AM

## Session 4: Multiple Myeloma

Chairmen: Kenneth C. Anderson, Mario Boccadoro

- Staging and prognosis of multiple myeloma
- First line therapy for young patients
- First line therapy for elderly patients
- New drugs in multiple myeloma
- Curing myeloma – How to define and accomplish

Mario Boccadoro  
Elena Zamagni  
Antonio P. Palumbo  
Kenneth C. Anderson

Bart Barlogie

10:00 AM - 11:00 AM **Open Coffee**

10:15 AM - 12:30 PM

## Session 5: Acute Lymphoid Leukemia

Chairmen: Carmino De Souza, Robin Foà

- ALL therapy in adults
- ALL therapy in children
- T ALL: new therapeutic perspectives?
- Transplant in ALL: which one and when
- Ph-positive ALL: the German approach
- Ph-positive ALL: the Italian approach

Dieter Hoelzer  
Andrea Biondi  
Jan Cools  
Hervé Dombret  
Oliver Ottmann  
Robin Foà

12:30 PM - 1:00 PM

## John Moloney Memorial Lecture

Introduction: Federico Caligaris-Cappio

B-raf and HCL

Brunangelo Falini

1:00 PM - 2:00 PM **Lunch**

2:00 PM - 3:30 PM

## Session 6: Focus on iron

Chairmen: Clara Camaschella, Eliezer Rachmilewitz

- Molecular biology of iron overload
- Methods to quantify iron overload
- Intracellular damage of iron overload in MDS
- Chelation therapy in chronic anemias
- Chelation therapy in MDS

Clara Camaschella  
Antonio Piga  
Eliezer Rachmilewitz  
Maria D. Cappellini  
Daniela Cilloni





3:30 PM - 4:00 PM

## Peter Hans Hofschneider Memorial Lecture

Introduction: John Goldman

Animal Models to study human leukemogenesis

Rick Van Etten

4:00 PM - 5:00 PM      **Open Coffee**

4:00 PM - 5:30 PM

## Session 7: Focus on Stem Cell Transplant

Chairmen: Jane Apperley, Angelo Michele Carella

- Haploidentical transplant
- Cord blood transplant
- Transplant in CML
- Allo SCT for congenital anemias:  
the example of Diamond Blackfan disease

Nicholas Kröger  
Francesco Frassoni  
Jane Apperley

Franca Fagioli

5:30 PM - 6:00 PM

## Howard Temin Memorial lecture

Introduction: Tariq Mughal

Deconstructing the molecular genetics of human  
leukemia and its therapeutic implications

Pier Paolo Pandolfi

6:00 PM - 7:30 PM

## Celgene Sponsored Symposium with Cocktail Dinner

Therapeutic Strategies for Haematological Malignancies - an Update

Chairman: Wolf-Karsten Hofmann

- Welcome and introduction
- Status quo on the treatment of  
lower-risk del(5q) MDS patients
- Emerging maintenance strategies for  
AML patients undergoing intensive therapy
- Opportunities in the changing treatment  
landscape of MM
- Novel treatment strategies in PTCL
- Discussion and close

Wolf-Karsten Hofmann

Valeria Santini

Alan Burnett

Antonio Palumbo

Paolo Corradini

Wolf-Karsten Hofmann

# Friday, September 13, 2013

8:30 AM - 10:30 AM

## Session 8: MPNs

Chairmen: Francisco Cervantes, Tariq Mughal

- New mutations and pathogenesis of myeloproliferative neoplasms
- Preclinical models of novel targets for treatment
- Management of polycythemia vera
- Prognostic scores in primary myelofibrosis
- Therapeutic approaches in myelofibrosis

William Vainchenker

Alessandro M. Vannucchi

Tiziano Barbui

Francisco Cervantes

Giovanni Barosi

10:00 AM - 11:00 AM Open Coffee

10:30 AM - 12:30 PM

## Session 9: Chronic Myeloid Leukemia

Chairmen: Francois Guilhot, Anna Turkina

- ELN recommendations in 2013
- New prognostic markers in CML
- First line therapy in CML: which is the best?
- Can treatment discontinuation become the ultimate goal of CML therapy?
- New targets in CML therapy
- Open problems in CML research

Michele Baccarani

Martin Müller

Andreas Hochhaus

François Guilhot

Danilo Perrotti

John Goldman

12:30 PM - 1:00 PM

## Sol Spiegelman Memorial Lecture

Introduction: Arsène Burny

CML in 2013: how can we best predict and improve outcome?

Rüdiger Hehlmann

1:00 PM - 2:00 PM Lunch and Poster walking

Chairmen: Felicetto Ferrara, Giorgina Specchia

1:00 PM - 1:45 PM IACRLRD General Assembly

2:00 PM - 4:00 PM

## Session 10: Myelodysplastic Syndromes

Chairmen: Michael Lübbert, Norbert Vey

- Genetic Alterations in MDS: which are the driver mutations?

H. Phillip Koeffler



- Towards a molecular classification and prognostication of MDS Mario Cazzola
- Therapeutic interventions to target the molecular defects in lower-risk MDS Eva Hellström-Lindberg
- Recent advances in epigenetic therapy of MDS and secondary AML Michael Lübbert
- Activities of the GFM-Study-Group: from anti-angiogenetic therapy to allografting of MDS Norbert Vey
- Activities of the German MDS Research Consortium Wolf-Karsten Hofmann

4:00 PM - 5:00 PM **Open Coffee**

4:00 PM - 5:30 PM

## Session 11: Chronic Lymphocytic Leukemia

Chairmen: Federico Caligaris-Cappio, Marina Liberati

- Molecular pathogenesis of CLL and its evolution Davide Rossi
- Prognostic markers in CLL Emili Montserrat
- Monoclonal B-cell lymphocytosis Paolo Ghia
- Molecular genetics of high-risk chronic lymphocytic leukemia Gianluca Gaidano
- Novel therapies for CLL Amy J. Johnson

5:30 PM - 6:00 PM

## Frank Rauscher Memorial Lecture

Introduction: Tariq Mughal

Hematological neoplasms after exposure to ionizing radiations

Robert P. Gale

6:00 PM - 7:30 PM

## Novartis Sponsored Symposium with Cocktail Dinner

Optimal management of Myeloproliferative disorders

Chairmen: Francis Giles, Gianantonio Rosti

- Path to cure: protocols aiming to therapy discontinuation François-Xavier Mahon
- Endpoints and surrogate markers in clinical trials Joëlle Guilhot
- How to eradicate the minimal residual disease in CML Francis Giles
- New perspective in the management of MPNs Francesco Passamonti

# Saturday, September 14, 2013

8:30 AM - 10:00 AM

## Session 12: Nanotechnologies for innovative clinical research

Chairmen: Giovanni Martinelli, Fabrizio Pane

- Methods to identify novel candidate cancer genes:  
what is new? Alessandro Morotti
- The “essential” molecular lab for present clinical practice Fabrizio Pane
- Whole genome sequencing: a true perspective  
in clinical practice? Giovanni Martinelli
- Ultra-deep sequencing: the future of  
mutation analysis? Simona Soverini

10:00 AM - 11:00 AM **Open Coffee**

10:00 AM - 12:30 PM

## Session 13: Viruses and hematological malignancies

Chairmen: Luigi Chieco Bianchi, Genoveffa Franchini

- Models for HIV eradication strategies Genoveffa Franchini
- B cell lymphoma in HIV infection - does HIV  
have anything to do with it? Alfredo Garzino Demo
- Hematological neoplasms and viral Infections Toshiki Watanabe
- Adult T-Cell leukemia Arinobu Tojo
- Regulation of oligoclonality in HTLV-1  
infection Charles R.M. Bangham
- Historical overview on the roots of  
comparative research in leukemia Günter Pasternak

12:30 PM - 1:00 PM

## Charlotte Friend Memorial Lecture

Introduction: Toshiki Watanabe

PNH: a clonal non-neoplastic hematopoietic disease Lucio Luzzatto

1:00 PM - 2:00 PM **Lunch**



2:00 PM - 2:30 PM

## Special Lecture

Introduction: Giuseppe Saglio

Molecular pathogenesis of Diffuse Large B cell lymphomas

Riccardo Dalla Favera

2:30 PM - 4:30 PM

## Session 14: Lymphoid malignancies

Chairmen: Riccardo Dalla Favera, Stefano Sacchi

- Follicular Lymphomas
- Diffuse Large B-Cell Lymphomas therapy
- The predictive value of PET
- Auto and allo transplantation in PTCL: what can be considered a standard?

Corrado Tarella  
Carmino De Souza  
Andrea Gallamini

Paolo Corradini

4:30 PM - 4:45 PM Closing remarks

Giuseppe Saglio

# Poster

## Acute Myeloid Leukemia

### P01

BENEFITS OF THE USE OF AZACITDINE IN PATIENTS WITH AML REFRACTORY OR RELAPSED AFTER INTENSIVE CHEMOTHERAPY

Cerchione C., Giagnuolo G., Angelillo P., Avilia S., Vitagliano O., Pugliese N., Marano L., Pareto A., Alfinito F., Pane F., Cerciello G. (Napoli - Italy)

### P02

T CELL-MEDIATED IMMUNOMODULATION AS A NEW POTENTIAL MECHANISM IN ACUTE MYELOID LEUKEMIA DEVELOPMENT

De Matteis S., Carloni S., Napoletano R., Fabbri F., Zoli W., Musuraca G. (Meldola, Forlì - Italy)

### P03

CYTOGENETIC ABNORMALITIES OF ISOCHROMOSOME 17q10 & CHROMOSOME'S X TRISOMY IN A PATIENT WITH SECONDARY ACUTE MYELOID LEUKEMIA PRESENTED WITH CARDIAC TAMPONADE

Dizdari A., Sina S., Di Giovanni Bezzi C., Pugliese S. (Bologna - Italy)

### P04

SUCCESSFUL SALVAGE TREATMENT WITH CLOFARABINE AND CYTARABINE IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

Malato A., Felice R., Magrin S., Turri D., Scimè R., Santoro A., Di Bella R., Salemi D., Acquaviva F., Fabbiano F. (Palermo - Italy)

### P05

DIAGNOSTIC CHARACTERIZATION OF ACUTE PROMYELOCYTIC LEUKEMIA AND TARGETED THERAPY IN THIS LEUKEMIA

Nasouhi pur S. (Tabriz - Iran)

## Chronic Lymphocytic Leukemia

### P06

THE EXPRESSION OF MICRORNA-34A IS A HIGHLY RELIABLE MARKER FOR IMPAIRMENT OF P53-PATHWAY IN CLL: DEVELOPMENT OF CLINICALLY APPLICABLE ASSAY

Mraz M., Cerna K., Musilova K., Malcikova J., Plevova K., Pavlova S., Tichy B., Brychtova Y., Doubek M., Mayer J., Trbusek M., Pospisilova S. (Brno - Czech Republic)

### P07

B-CHRONIC LYMPHOCYTIC LEUKEMIA WITH ABERRANT EXPRESSION OF CD103: ANALYSIS OF PROGNOSTIC FACTORS

Muccio V.E., Aschero S., Ferrero S., Saraci E., Gilestro M., Bruno B., Omedé P., Boccardo M. (Torino - Italy)



## MPNs

### P08

ANALYSIS OF FREQUENCY AND PROGNOSTIC IMPACT OF ASXL1, EZH2, IDH1, IDH2, AND SRSF2 MUTATIONS IN PATIENTS WITH SECONDARY MYELOFIBROSIS  
Biamonte F., Rotunno G., Guglielmelli P., Vannucchi A.M. (Firenze - Italy)

### P09

IDIOPATHIC MYELOFIBROSIS (IMF): DISEASE CHARACTERISTICS AND PERIPHERAL BLOOD CD34+ CELLS  
Improta S., Villa M.R., Esposito M., Tommasino C., Fossati G., Mastrullo L. (Napoli - Italy)

### P10

PKC412 (MIDOSTAURIN) IS SAFE AND HIGHLY EFFECTIVE IN AGGRESSIVE SYSTEMIC MASTOCYTOSIS PATIENTS: THE BOLOGNA EXPERIENCE  
Papayannidis C., Soverini S., De Benedittis C., Abbenante M., Sartor C., Parisi S., Paolini S., Iacobucci I., Frabetti F., Lani E., Ottaviani E., Ferrari A., Guadagnuolo V., Conficoni A., Baldazzi C., Testoni N., Martinelli G. (Bologna - Italy)

### P11

INTERFERON SIGNATURE PREDICTS RESPONSIVENESS IN ESSENTIAL THROMBOCYTHEMIA  
Pugliese N., Quintarelli C., De Angelis B., Errichiello S., Marano L., Esposito N., Cerchione C., Picardi M., Martinelli V., Pane F. (Napoli - Italy)

### P12

IN VITRO SINERGISTIC INHIBITORY EFFECTS USING COMBINATION OF INTERFERON ALPHA AND ALL-TRANS RETINOIC ACID IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS (MPN)  
Pugliese N., Quintarelli C., De Angelis B., Errichiello S., Marano L., Raia M., Cerchione C., Del Vecchio L., Picardi M., Martinelli V., Pane F. (Napoli - Italy)

## Multiple Myeloma

### P13

SERUM FREE LIGHT CHAINS (sFLC) QUANTIFICATION IN MONOCLONAL GAMMOPATHIES AND MULTIPLE MYELOMA PATIENTS  
Gagliardi A., Improta S., Villa M.R., Lucania A., Russo A., Dente B., Mastrullo L. (Napoli - Italy)

**P14****LENALIDOMIDE CONTINUOUS TREATMENT IN MULTIPLE MYELOMA ELDERLY PATIENTS**

Gagliardi A., Improta S., Esposito M., Della Cioppa P., Nitrato Izzo G., Mastrullo L. (Napoli - Italy)

**P15****ABNORMAL CHROMOSOME 1 AND CD19+/CD117- PLASMA CELLS IMMUNOPHENOTYPE IN ELDERLY MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS**

Caltagirone S.A., Ruggeri M., Aschero S., Marzanati E., Gay F., Cavallo F., Muccio V.E., Saraci E., Palumbo A., Rodeghiero F., Di Renzo N., Ciceri F., Ferrara F., Passera R., Boccadoro M., Omedè P. (Torino - Italy, Italian Multiple Myeloma Network - GIMEMA)

**P16****MANAGEMENT OF MULTIPLE MYELOMA WITH BENDAMUSTINE: A FURTHER OPTION FOR RELAPSED AND REFRACTORY PATIENTS**

Cerchione C., Madonna E., Marano L., Pugliese N., Seneca E., Avilia S., Cerciello G., Pane F., Catalano L. (Napoli - Italy)

**P17****PEGFILGRASTIM IN THE MANAGEMENT OF POSTCHEMOTHERAPY FEBRILE NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA**

Cerchione C., Pugliese N., Marano L., Cerciello G., Avilia S., Seneca E., Pane F., Catalano L. (Napoli - Italy)

## Myelodysplastic Syndromes

**P18****EVALUATION OF ERYTHROPOIETIC ASPECTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES RESPONDERS TO ERYTHROPOIESIS STIMULATING AGENTS (ESAs)**

Cerchione C., Danise P., Vitagliano O., Cerciello G., Pareto A., Soriente I., D'Arco A.M., Pane F., Alfinito F. (Napoli, Nocera Inferiore - Italy)

## Stem cell transplant

**P19****PERIPHERALLY INSERTED CENTRAL CATHETERS (PICCS) CAN BE SUCCESSFULLY UTILIZED IN HAEMATOLOGICAL PATIENTS RECEIVING INTENSIVE CHEMOTHERAPY OR ALLOGENEIC/AUTOLOGOUS STEM CELL TRANSPLANTATION**

Malato A., Luppino A., Pipitone R., Donà M.G., Acquaviva F., Di Bella R., Scimè R., Fabbiano F. (Palermo - Italy)





## General information

### MEETING VENUE

#### Lingotto Conference Center

Via Nizza, 280 - 10126 Torino - Italy

Ph.: +39 011 63 11 711

[www.centrocongressilingotto.it](http://www.centrocongressilingotto.it)

### HOW TO REACH THE MEETING VENUE

You can find the information to reach to meeting venue on the website: [www.iacrlrd2013.com](http://www.iacrlrd2013.com).

### LANGUAGE

The Conference will be in English with no simultaneous translation into other languages.

### BADGES

All registered participants, speakers and exhibitors will be given a badge which they must wear to be admitted to the scientific sessions.

### REGISTRATION FEES

IACRLRD members	free
Participants under 35 years	Euro 200,00 (VAT included)
Others	Euro 500,00 (VAT included)

The registration fees include:

- participation in the scientific sessions
- access to the exhibition area
- attendance certificate
- lunches and coffee breaks
- welcome cocktail
- abstracts of the meeting

### HOW TO REGISTER

Fill in the form available online on the website [www.iacrlrd2013.com](http://www.iacrlrd2013.com)

### HOTEL RESERVATION

#### Viaggi Salvadori Srl

Via Ugo Bassi, 13 - 40121 Bologna - Italy

Phone +39 051 263281 - Fax +39 051 224426

E-mail: [turin@viaggisalvadori.it](mailto:turin@viaggisalvadori.it)

Download the Hotel Registration Form from the website of the meeting: [www.iacrlrd2013.com](http://www.iacrlrd2013.com), fill in and send it to Viaggi Salvadori.

## Scientific information

### ATTENDANCE CERTIFICATE

A certificate will be given to all participants at the end of the Conference.

### ITALIAN CME

The Italian Ministry of Health allows:

- **no. 7,5 credits** for physicians, biologists and technicians who attend the meeting on September 11th and 12th, 2013
- **no. 8 credits** for physicians, biologists and technicians who attend the meeting on September 13th and 14th, 2013

### EUROPEAN CME

The program of the “XXVI Symposium IACRLRD” has been reviewed and approved for CME accreditation by the European Hematology Association CME Unit. The EHA-CME Unit has approved this educational activity for **no. 31 CME credits** for physicians and biologists.

To request credits, please fill in the questionnaire and return it to the registration desk at the end of the meeting. We remind you that it is necessary to create an EHA-CME account on the EHA website: <http://eha-cme.org>.

### WORLD COMMITTEE MEETINGS

There are 3 World Committee meetings during the Congress scheduled as follows:

1. Wednesday, September 11 9:00-10:30 AM
2. Wednesday, September 11 1:00-1:45 PM
3. Thursday, September 12 1:00-1:45 PM

### GENERAL ASSEMBLY

The IACRLRD General Assembly is scheduled on Friday, September 13 at lunch time in plenary session.

During the General Assembly there will be the election or confirmation of the new World Committee members and the advertisement to become IACRLRD members. The General Assembly is opened to all participants, but with voting rights restricted to members. Membership forms are available at the registration desk.

### CHANGES

Part of the program may be changed if necessary without notice.



## Acknowledgements

CELGENE  
NOVARTIS ONCOLOGY

BRISTOL MYERS SQUIBB  
OTSUKA

ALEXION  
ARIAD  
JANSSEN  
SPECTRUM PHARMACEUTICAL B.V.

MUNDIPHARMA PHARMACEUTICALS  
PFIZER ITALIA  
PIERRE FABRE  
ROCHE  
SHIRE  
TEVA ITALIA

Scientific Secretariat

**Giuseppe Saglio**

Div. Biological and Clinical Sciences

S. Luigi Hospital - University of Turin

Reg. Gonzole, 10 - 10043 Orbassano - TO, Italy

Phone +39 011 6705473-76 - Fax +39 011 9038636

e-mail: [giuseppe.saglio@unito.it](mailto:giuseppe.saglio@unito.it)

Organizing Secretariat

**Studio E.R. Congressi - Triumph Group**

Via Marconi, 36 - 40122 Bologna, Italy

Phone +39 051 4210559 - Fax +39 051 4210174

e-mail: [ercongressi@triumphgroup.it](mailto:ercongressi@triumphgroup.it)

[www.ercongressi.it](http://www.ercongressi.it)